Biotech IPOs: Are They Poised For a Major Surge This Year?
Somewhere along the way from the heady days of the dot-com era in 2000 the "magic" of achieving a successful biotech initial public offering (IPO) seems to have been lost. Time was that for biotech companies and the venture capitalists who invested in them, a public stock offering was the first major milestone of business and financial success – a preferred exit strategy for VCs and an opportunity for companies to access future public market capital financings and adequately fund their product pipeline development.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5476
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST